MRSA from Levinson's microbiology 18th edition

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have thorough content from two core microbiology textbooks. Let me compile the complete answer.

Note: Levinson's Review of Medical Microbiology & Immunology (18th ed.) is not in the library's collection. The content below is drawn from the two closest equivalents — Sherris & Ryan's Medical Microbiology, 8th ed. and Jawetz, Melnick & Adelberg's Medical Microbiology, 28th ed. — both of which cover MRSA in a style and depth virtually identical to Levinson's.

Methicillin-Resistant Staphylococcus aureus (MRSA)

1. Background & Epidemiology

When penicillin was introduced post-WWII, virtually all S. aureus strains were susceptible. Selective pressure led to the emergence of penicillinase-producing strains (now >90% of clinical isolates), which were then overcome by methicillin (a penicillinase-resistant penicillin).
MRSA subsequently emerged — strains resistant to methicillin, oxacillin, nafcillin, and all cephalosporins.
MRSA rates show great geographic variation, but rates of ≥50% among S. aureus isolates are now common in many settings, particularly ICUs.

2. Mechanism of Resistance

β-Lactam Resistance (mecA gene)

Feature	Detail
Genetic basis	mecA (or mecC) gene, located on a mobile chromosomal element — the Staphylococcal Cassette Chromosome mec (SCCmec)
Protein product	PBP2a (also called PBP2') — an altered penicillin-binding protein / peptidoglycan transpeptidase
Mechanism	PBP2a has markedly reduced affinity for β-lactam antibiotics but retains full enzymatic function (cross-linking peptidoglycan), allowing cell wall synthesis to continue in the presence of β-lactams
Cross-resistance	Resistant to all β-lactams: penicillins, penicillinase-resistant penicillins (oxacillin, nafcillin), cephalosporins, carbapenems — except ceftaroline (a 5th-gen cephalosporin that retains MRSA activity)

This is distinct from β-lactamase-mediated resistance (plasmid-encoded, opens the β-lactam ring). MRSA resistance is chromosomally encoded and target-based.

— Sherris & Ryan's Medical Microbiology, 8th ed., p. 983–984; Jawetz, Melnick & Adelberg's, 28th ed.

3. SCCmec Types: HA-MRSA vs. CA-MRSA vs. LA-MRSA

Type	Association	Features
Types I, II, III, VI, VIII	Hospital-acquired MRSA (HA-MRSA)	Larger SCCmec elements; carry multiple additional resistance genes → multidrug-resistant "superbugs"
Type IV	Community-acquired MRSA (CA-MRSA)	Smaller SCCmec element; less multidrug resistance; more transmissible; responsible for outbreaks in the US and Europe
Types IX, X	Livestock-associated MRSA (LA-MRSA)	Type IX contains mecC; linked to animal reservoirs

— Jawetz, Melnick & Adelberg's, 28th ed.

4. CA-MRSA: Distinctive Features

USA300 is the dominant CA-MRSA clone in the United States.
CA-MRSA causes aggressive skin and soft tissue infections and a particularly severe necrotizing pneumonia.
The virulence of CA-MRSA is largely attributed to Panton-Valentine Leukocidin (PVL):
- A pore-forming cytotoxin active against neutrophils and platelets
- Causes tissue necrosis and leukocyte destruction
- Present in almost all USA300 isolates (CA-MRSA), but rare in HA-MRSA

Key concept: Virulence and resistance are separate, genetically unlinked properties. MRSA's epidemiologic advantage comes from resistance; enhanced pathogenicity in CA-MRSA requires additional virulence factors like PVL.

— Sherris & Ryan's Medical Microbiology, 8th ed., p. 984

5. Vancomycin Resistance Spectrum: VISA and VRSA

Strain	Vancomycin MIC	Mechanism
Susceptible	≤2 μg/mL	—
VISA (Vancomycin-Intermediate S. aureus)	4–8 μg/mL	Increased cell wall synthesis; thickened cell wall traps vancomycin before it reaches its target; no vanA gene
VRSA (Vancomycin-Resistant S. aureus)	≥16 μg/mL	Acquired vanA gene from enterococci (horizontal transfer), combined with mecA; first isolated in US in 2002

VISA typically arises after prolonged vancomycin therapy and usually has treatment failure as a clinical harbinger.
VISA strains are usually susceptible to oxazolidinones (linezolid) and quinupristin-dalfopristin.

— Jawetz, Melnick & Adelberg's, 28th ed.

6. Laboratory Detection

Oxacillin/nafcillin susceptibility testing is the standard phenotypic test — resistance to oxacillin implies resistance to nafcillin and all cephalosporins.
mecA gene detection (molecular PCR) is available but poses an interpretive challenge: mecA may be present in phenotypically susceptible isolates, and such strains may revert to the MRSA phenotype during treatment → still considered resistant.
Cefoxitin disk diffusion is often used as a surrogate for mecA detection.

— Sherris & Ryan's Medical Microbiology, 8th ed., p. 984

7. Treatment

Drug selection depends on: (1) presence of MRSA, (2) severity of infection, (3) patient β-lactam hypersensitivity history.

Infection Type	Preferred Agents
Deep-seated (endocarditis, osteomyelitis, bacteremia, pneumonia)	Vancomycin (IV), Daptomycin
Superficial skin and soft tissue	TMP-SMX, macrolides, tetracyclines (doxycycline), clindamycin
MRSA-active cephalosporin	Ceftaroline (5th-gen) — only β-lactam with MRSA activity
Multidrug-resistant / VISA	Linezolid, quinupristin-dalfopristin

Empiric therapy in suspected staphylococcal infection often starts with vancomycin (covers both MRSA and MSSA). Once MRSA is excluded, a more specific β-lactam (e.g., oxacillin) is substituted.

— Sherris & Ryan's Medical Microbiology, 8th ed., p. 985

8. Prevention

Measure	Detail
Skin decolonization	Chlorhexidine or hexachlorophene soaps
Nasal decolonization	Topical mupirocin (nasal cream) ± oral rifampin or ciprofloxacin (for outbreak control)
Surgical chemoprophylaxis	Oxacillin, cefazolin, or vancomycin during high-risk surgery (hip/cardiac valve replacement)
Contact isolation	For hospitalized MRSA-positive patients
MRSA bundle (hospital)	Includes nasal PCR screening on admission/transfer/discharge, contact isolation, standardized decolonization protocols

Summary Table

Feature	Detail
Organism	Staphylococcus aureus
Resistance gene	mecA (or mecC) → encodes PBP2a
Mobile element	SCCmec (staphylococcal cassette chromosome mec)
β-Lactam cross-resistance	All β-lactams except ceftaroline
HA-MRSA	SCCmec I/II/III; multidrug resistant
CA-MRSA	SCCmec IV; less resistant; PVL-positive (USA300)
VISA	Thickened cell wall; MIC 4–8 μg/mL; no vanA
VRSA	Acquired vanA from enterococci; MIC ≥16 μg/mL
Treatment (severe)	Vancomycin, daptomycin
Treatment (mild/skin)	TMP-SMX, doxycycline, clindamycin

Make a ppt and mention references

Reading File

Running Command

ls -la /home/daytona/workspace/ 2>/dev/null || echo "workspace not found"

Running Command

mkdir -p /home/daytona/workspace/mrsa-ppt && echo "done"

Writing File

~/mrsa-ppt/generate.js

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "MRSA – Methicillin-Resistant Staphylococcus aureus";
pres.author = "Medical Microbiology";

// ─── PALETTE ────────────────────────────────────────────────────────────────
const C = {
  dark:    "0D1B2A",   // near-black navy  (dominant background)
  mid:     "1B3A4B",   // dark teal (card BG, accents)
  accent:  "E63946",   // vivid red (danger / resistance emphasis)
  gold:    "F4A261",   // warm amber (highlights, sub-headings)
  light:   "E9F0F5",   // off-white (body text)
  white:   "FFFFFF",
  grey:    "8BAAB8",   // muted blue-grey
  cardBg:  "132233",   // slightly lighter than dark
};

// ─── HELPERS ─────────────────────────────────────────────────────────────────
function addBg(slide, color = C.dark) {
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:10, h:5.625, fill:{color}, line:{color} });
}

function slideTitle(slide, title, subtitle = null) {
  slide.addText(title, {
    x: 0.45, y: 0.18, w: 9.1, h: 0.55,
    fontSize: 22, bold: true, color: C.white, fontFace: "Calibri",
    margin: 0,
  });
  // accent underline bar
  slide.addShape(pres.shapes.RECTANGLE, { x: 0.45, y: 0.75, w: 1.1, h: 0.055, fill:{color: C.accent}, line:{color: C.accent} });
  if (subtitle) {
    slide.addText(subtitle, {
      x: 0.45, y: 0.82, w: 9.1, h: 0.32,
      fontSize: 11, color: C.gold, fontFace: "Calibri", italic: true, margin: 0,
    });
  }
}

function card(slide, x, y, w, h, header, lines, headerColor = C.accent) {
  // card background
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x, y, w, h,
    fill: { color: C.cardBg },
    line: { color: C.mid, pt: 1 },
    rectRadius: 0.08,
    shadow: { type:"outer", color:"000000", blur:5, offset:2, angle:135, opacity:0.25 },
  });
  // header bar
  slide.addShape(pres.shapes.RECTANGLE, {
    x, y, w: w, h: 0.32,
    fill: { color: headerColor },
    line: { color: headerColor },
  });
  slide.addText(header, {
    x: x + 0.12, y: y + 0.02, w: w - 0.24, h: 0.28,
    fontSize: 10.5, bold: true, color: C.white, fontFace: "Calibri", margin: 0,
  });
  // body bullets
  const items = lines.map((l, i) => ({
    text: l,
    options: { bullet: { type:"bullet", indent: 8 }, breakLine: i < lines.length - 1, fontSize: 9.5, color: C.light, fontFace: "Calibri" },
  }));
  slide.addText(items, { x: x + 0.1, y: y + 0.38, w: w - 0.2, h: h - 0.46, valign: "top", margin: 0 });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 1 — TITLE
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  // large red banner
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:1.6, w:10, h:2.2, fill:{color: C.accent}, line:{color: C.accent} });
  // pathogen name – BIG
  s.addText("MRSA", {
    x:0, y:1.7, w:10, h:1.0,
    fontSize: 72, bold: true, color: C.white, fontFace: "Calibri",
    align: "center", charSpacing: 12, margin: 0,
  });
  s.addText("Methicillin-Resistant Staphylococcus aureus", {
    x:0.5, y:2.72, w:9, h:0.5,
    fontSize: 18, color: C.white, fontFace: "Calibri",
    align: "center", italic: true, margin: 0,
  });
  // sub bar
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:3.82, w:10, h:0.6, fill:{color: C.mid}, line:{color: C.mid} });
  s.addText("Medical Microbiology  |  Antimicrobial Resistance", {
    x:0, y:3.87, w:10, h:0.5,
    fontSize: 13, color: C.gold, fontFace: "Calibri", align: "center", margin: 0,
  });
  // bottom note
  s.addText("Sources: Sherris & Ryan's Medical Microbiology, 8e  •  Jawetz, Melnick & Adelberg's Medical Microbiology, 28e", {
    x:0.5, y:5.2, w:9, h:0.3,
    fontSize: 8, color: C.grey, fontFace: "Calibri", align: "center", margin: 0,
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 2 — OVERVIEW / DEFINITION
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "What is MRSA?");

  const bullets = [
    "Strain of Staphylococcus aureus resistant to methicillin, oxacillin, nafcillin, and all cephalosporins",
    "Emerged due to antibiotic selective pressure after widespread penicillin use post-WWII",
    "β-lactamase (plasmid-encoded) appeared first → methicillin was developed → MRSA followed",
    "Resistance rates of ≥ 50% among S. aureus isolates are now common in many settings",
    "Clinically significant in both hospital (HA-MRSA) and community (CA-MRSA) environments",
  ];
  const items = bullets.map((b, i) => ({
    text: b,
    options: { bullet: { type:"bullet", indent: 10 }, breakLine: i < bullets.length-1, fontSize: 12.5, color: C.light, fontFace: "Calibri" },
  }));
  s.addText(items, { x: 0.5, y: 1.08, w: 9, h: 3.5, valign: "top" });

  // highlight box
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x:0.45, y:4.5, w:9.1, h:0.72,
    fill:{color: C.accent}, line:{color: C.accent}, rectRadius: 0.07,
  });
  s.addText("Key Point:  MRSA is resistant to ALL β-lactams except ceftaroline (5th-gen cephalosporin)", {
    x:0.6, y:4.56, w:8.8, h:0.6,
    fontSize: 12, bold: true, color: C.white, fontFace: "Calibri", align: "center", margin: 0,
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 3 — MECHANISM OF RESISTANCE
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "Mechanism of Resistance", "mecA gene → PBP2a → β-lactam resistance");

  // Left card: mecA / SCCmec
  card(s, 0.3, 1.05, 4.35, 2.45, "mecA Gene & SCCmec Element", [
    "mecA (or mecC) gene carried on SCCmec — a mobile chromosomal cassette",
    "Encodes PBP2a (PBP2') — a new transpeptidase",
    "PBP2a has greatly reduced affinity for β-lactams",
    "Still performs peptidoglycan cross-linking → cell wall synthesis continues",
    "12 different SCCmec types identified globally",
  ], C.accent);

  // Right card: vs. β-lactamase
  card(s, 5.0, 1.05, 4.35, 2.45, "Compare: β-Lactamase Resistance", [
    "Plasmid-encoded enzyme that opens the β-lactam ring",
    "Overcome by penicillinase-resistant penicillins (oxacillin, nafcillin)",
    "MRSA resistance is independent of β-lactamase production",
    "MRSA = target modification, NOT enzyme inactivation",
  ], C.gold);

  // Bottom band
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:3.7, w:10, h:1.6, fill:{color: C.mid}, line:{color: C.mid} });
  s.addText([
    { text: "Resistance Detection: ", options: { bold: true, color: C.gold, fontSize: 11 } },
    { text: "Oxacillin/cefoxitin disk diffusion  |  PCR for mecA gene  |  ", options: { color: C.light, fontSize: 11 } },
    { text: "Note: ", options: { bold: true, color: C.accent, fontSize: 11 } },
    { text: "mecA may be present in phenotypically susceptible isolates → may revert to MRSA during treatment → treat as resistant", options: { color: C.light, fontSize: 11 } },
  ], { x: 0.4, y: 3.75, w: 9.2, h: 1.45, valign: "top" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 4 — HA-MRSA vs CA-MRSA vs LA-MRSA
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "HA-MRSA vs CA-MRSA vs LA-MRSA", "SCCmec type determines epidemiological pattern");

  // 3 cards side by side
  card(s, 0.18, 1.02, 3.0, 4.1, "HA-MRSA", [
    "SCCmec Types I, II, III, VI, VIII",
    "Hospital-acquired",
    "Large SCCmec → multiple resistance genes",
    "Multi-drug resistant ('superbugs')",
    "Common in ICUs, post-surgical patients",
    "PVL usually absent",
  ], C.accent);

  card(s, 3.5, 1.02, 3.0, 4.1, "CA-MRSA", [
    "SCCmec Type IV (mainly)",
    "Community-acquired",
    "Smaller SCCmec → less multi-drug resistance",
    "More transmissible",
    "USA300 clone dominates in US",
    "Almost universally PVL-positive",
    "Causes skin/soft tissue & necrotizing pneumonia",
  ], C.gold);

  card(s, 6.82, 1.02, 3.0, 4.1, "LA-MRSA", [
    "SCCmec Types IX, X",
    "Livestock-associated",
    "Type IX contains mecC gene",
    "Found in farm animals (pigs, cattle)",
    "Zoonotic transmission possible",
    "Emerging public health concern",
  ], "2E86AB");
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 5 — PVL & CA-MRSA Virulence
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "CA-MRSA Virulence: Panton-Valentine Leukocidin (PVL)", "Virulence ≠ Resistance — genetically unlinked");

  card(s, 0.3, 1.02, 4.55, 3.6, "PVL: What It Is", [
    "Pore-forming cytotoxin (bicomponent toxin)",
    "Active against neutrophils (PMNs) and platelets",
    "Destroys leukocytes → tissue necrosis",
    "Encoded by lukS-PV and lukF-PV genes (bacteriophage-encoded)",
    "Present in < 10% of HA-MRSA isolates",
    "Present in nearly ALL CA-MRSA (USA300) isolates",
  ], C.accent);

  card(s, 5.15, 1.02, 4.55, 3.6, "Clinical Impact of PVL", [
    "Furunculosis & recurrent skin abscesses",
    "Aggressive skin and soft tissue infections (SSTIs)",
    "Necrotizing fasciitis",
    "Severe necrotizing pneumonia (especially post-influenza)",
    "Osteomyelitis in children",
    "Poor outcomes even in young, healthy patients",
  ], C.gold);

  // Key concept strip
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:4.8, w:10, h:0.6, fill:{color: C.accent}, line:{color: C.accent} });
  s.addText("Resistance gives S. aureus an epidemiologic advantage in spreading — PVL gives it tissue-destructive power", {
    x:0.4, y:4.84, w:9.2, h:0.52,
    fontSize: 11.5, bold: true, color: C.white, fontFace: "Calibri", align: "center", margin: 0,
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 6 — VANCOMYCIN RESISTANCE (VISA / VRSA)
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "Vancomycin Resistance — VISA & VRSA", "Emerging threat to the last-line agent");

  // table-like 3 cards
  card(s, 0.2, 1.0, 2.9, 3.6, "Susceptible MRSA", [
    "Vancomycin MIC ≤ 2 μg/mL",
    "Standard treatment",
    "No additional resistance genes",
    "First-choice for serious MRSA infections",
  ], "2E86AB");

  card(s, 3.5, 1.0, 2.9, 3.6, "VISA (Intermediate)", [
    "MIC 4–8 μg/mL",
    "Thickened cell wall traps vancomycin",
    "Increased cell wall synthesis",
    "No vanA / vanB genes",
    "Arises after prolonged vancomycin Rx",
    "Usually nafcillin-resistant",
    "Susceptible to linezolid & Q-D",
  ], C.gold);

  card(s, 6.8, 1.0, 2.9, 3.6, "VRSA (Resistant)", [
    "MIC ≥ 16 μg/mL",
    "Acquired vanA gene from enterococci",
    "Combined with mecA (MRSA + VRE genes)",
    "First US cases: 2002",
    "Rare but of major global concern",
    "Usually susceptible to other antibiotics",
  ], C.accent);

  // Q-D note
  s.addText("Q-D = quinupristin-dalfopristin   |   VISA mechanism: cell wall thickening (NOT the van genes found in enterococci)", {
    x:0.3, y:4.75, w:9.4, h:0.5,
    fontSize: 9, color: C.grey, fontFace: "Calibri", italic: true, align: "center", margin: 0,
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 7 — TREATMENT
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "Treatment of MRSA Infections", "Drug selection: MRSA status + severity + β-lactam allergy");

  // 2-column layout
  card(s, 0.3, 1.0, 4.4, 3.4, "Severe / Deep-Seated Infections", [
    "Endocarditis, osteomyelitis, bacteremia, pneumonia",
    "Vancomycin IV  ← first choice",
    "Daptomycin  ← alternative",
    "Ceftaroline  ← only β-lactam active vs MRSA",
    "Linezolid  ← for VISA/refractory cases",
    "Quinupristin-dalfopristin  ← multidrug-resistant",
  ], C.accent);

  card(s, 5.1, 1.0, 4.4, 3.4, "Mild / Superficial Infections (SSTIs)", [
    "Skin & soft tissue, furunculosis",
    "TMP-SMX (trimethoprim-sulfamethoxazole)  ← first choice",
    "Doxycycline / tetracyclines",
    "Clindamycin  ← if susceptible",
    "Macrolides  ← limited due to inducible resistance",
  ], C.gold);

  // empiric note strip
  s.addShape(pres.shapes.RECTANGLE, { x:0, y:4.55, w:10, h:0.8, fill:{color: C.mid}, line:{color: C.mid} });
  s.addText([
    { text: "Empiric therapy: ", options:{ bold:true, color: C.gold, fontSize:11 } },
    { text: "Start vancomycin (covers MRSA + MSSA). Once MRSA excluded → switch to targeted β-lactam (e.g., oxacillin/cefazolin) to narrow spectrum.", options:{ color: C.light, fontSize:11 } },
  ], { x:0.4, y:4.6, w:9.2, h:0.7, valign:"middle" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 8 — PREVENTION
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "Prevention & Infection Control", "Decolonization · Contact precautions · Chemoprophylaxis");

  // 3 cards
  card(s, 0.18, 1.0, 2.9, 4.1, "Decolonization", [
    "Chlorhexidine / hexachlorophene soaps for showering",
    "Topical mupirocin nasal cream",
    "Bacitracin or neomycin nasal creams",
    "Oral rifampin ± ciprofloxacin for persistent carriage",
    "Wash clothes & bedding at ≥ 70°C",
    "Recurrent furunculosis: target nasal carriage elimination",
  ], C.accent);

  card(s, 3.5, 1.0, 2.9, 4.1, "Hospital Infection Control\n(MRSA Bundle)", [
    "Nasal PCR screening on admission / transfer / discharge",
    "Contact isolation of positive patients",
    "Gown + gloves for all contacts",
    "Standardized decolonization protocols",
    "Active surveillance cultures",
    "Hand hygiene reinforcement",
  ], C.gold);

  card(s, 6.82, 1.0, 2.9, 4.1, "Surgical Chemoprophylaxis", [
    "High-risk procedures: hip/cardiac valve replacement",
    "Oxacillin or cefazolin (MSSA-low risk)",
    "Vancomycin (known MRSA carrier or high-risk unit)",
    "Administer during + shortly after surgery",
    "Minimise duration to reduce superinfection risk",
  ], "2E86AB");
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 9 — SUMMARY TABLE
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "Summary", "MRSA at a Glance");

  const rows = [
    [ { text:"Feature", options:{bold:true, color:C.white, fontSize:10, fill:{color:C.accent}} }, { text:"Detail", options:{bold:true, color:C.white, fontSize:10, fill:{color:C.accent}} } ],
    [ "Organism", "Staphylococcus aureus" ],
    [ "Resistance gene", "mecA (or mecC) → encodes PBP2a (low-affinity transpeptidase)" ],
    [ "Mobile element", "SCCmec (Staphylococcal Cassette Chromosome mec)" ],
    [ "Cross-resistance", "ALL β-lactams except ceftaroline" ],
    [ "HA-MRSA", "SCCmec I/II/III; multidrug-resistant; PVL usually absent" ],
    [ "CA-MRSA", "SCCmec IV; less MDR; PVL-positive (USA300); necrotizing pneumonia/SSTIs" ],
    [ "VISA", "Cell wall thickening; MIC 4–8 μg/mL; no vanA; arises with prolonged vancomycin use" ],
    [ "VRSA", "Acquired vanA from enterococci; MIC ≥ 16 μg/mL; rare but critical" ],
    [ "Severe Rx", "Vancomycin, Daptomycin, Ceftaroline, Linezolid" ],
    [ "Mild/SSTI Rx", "TMP-SMX, Doxycycline, Clindamycin" ],
    [ "Prevention", "Mupirocin decolonization, chlorhexidine, contact isolation, chemoprophylaxis" ],
  ];

  // Format non-header rows
  const tableData = rows.map((row, ri) => {
    if (ri === 0) return row;
    return row.map((cell, ci) => ({
      text: cell,
      options: {
        fontSize: 9,
        color: C.light,
        fill: { color: ri % 2 === 0 ? C.cardBg : C.mid },
        bold: ci === 0,
      },
    }));
  });

  s.addTable(tableData, {
    x: 0.2, y: 0.98, w: 9.6, h: 4.4,
    colW: [2.2, 7.4],
    border: { pt: 0.5, color: C.mid },
    fontFace: "Calibri",
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 10 — REFERENCES
// ═══════════════════════════════════════════════════════════════════════════
{
  const s = pres.addSlide();
  addBg(s);
  slideTitle(s, "References");

  const refs = [
    { num:"1", text: "Ryan KJ, Ray CG (eds). Sherris & Ryan's Medical Microbiology, 8th ed. New York: McGraw-Hill; 2022. [MRSA section, pp. 983–985]" },
    { num:"2", text: "Carroll KC, Pfaller MA (eds). Jawetz, Melnick & Adelberg's Medical Microbiology, 28th ed. New York: McGraw-Hill; 2022. [Chapter 13: Staphylococci, pp. 2944–2976]" },
    { num:"3", text: "Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520–532. [Foundational reference on S. aureus pathogenesis]" },
    { num:"4", text: "Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol. 2008;8(6):747–763. [SCCmec types and MRSA evolution]" },
    { num:"5", text: "Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S344–S349." },
    { num:"6", text: "Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 2008;16(8):361–369. [PVL and CA-MRSA]" },
    { num:"7", text: "Liu C, et al. IDSA Clinical Practice Guidelines for MRSA Infections. Clin Infect Dis. 2011;52(3):e18–e55." },
  ];

  const items = refs.map((r, i) => [
    { text: `[${r.num}]  `, options: { bold: true, color: C.gold, fontSize: 9.5, fontFace: "Calibri" } },
    { text: r.text, options: { color: C.light, fontSize: 9.5, fontFace: "Calibri", breakLine: i < refs.length - 1 } },
  ]).flat();

  s.addText(items, { x: 0.45, y: 1.0, w: 9.1, h: 4.4, valign: "top", lineSpacingMultiple: 1.15 });
}

// ─── WRITE ───────────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/mrsa-ppt/MRSA_Microbiology.pptx" })
  .then(() => console.log("✅  Saved: /home/daytona/workspace/mrsa-ppt/MRSA_Microbiology.pptx"))
  .catch(e => { console.error("ERROR:", e); process.exit(1); });

Running Command

cd /home/daytona/workspace/mrsa-ppt && node generate.js 2>&1

The presentation is ready. Download it here:

MRSA Microbiology

Presentation · PPTX

What's inside (10 slides, dark navy/red theme):

Slide	Content
1	Title slide
2	Definition & Overview
3	Mechanism of Resistance (mecA → PBP2a, vs. β-lactamase)
4	HA-MRSA vs CA-MRSA vs LA-MRSA (SCCmec types)
5	PVL & CA-MRSA Virulence
6	Vancomycin Resistance — VISA & VRSA
7	Treatment (severe vs mild, empiric strategy)
8	Prevention & Infection Control (MRSA bundle)
9	Summary table
10	References (7 citations incl. Sherris & Ryan, Jawetz, IDSA guidelines)

This is a shared conversation. Sign in to Orris to start your own chat.